WallStreetZenWallStreetZen

NASDAQ: BGNE
Beigene Ltd Stock Forecast, Predictions & Price Target

Analyst price target for BGNE

Based on 4 analysts offering 12 month price targets for Beigene Ltd.
Min Forecast
$161.00+3.13%
Avg Forecast
$236.50+51.5%
Max Forecast
$345.00+121%

Should I buy or sell BGNE stock?

Based on 4 analysts offering ratings for Beigene Ltd.
Strong Buy
Strong Buy
3 analysts 75%
Buy
0 analysts 0%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BGNE stock forecasts and price targets.

BGNE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-09
lockedlocked$00.00+00.00%2024-04-08
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2024-03-19
lockedlocked$00.00+00.00%2024-02-27

1 of 1

Forecast return on equity

Is BGNE forecast to generate an efficient return?
Company
322.65%
Industry
76.61%
Market
81.23%
BGNE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BGNE forecast to generate an efficient return on assets?
Company
191.3%
Industry
31.22%
BGNE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BGNE earnings per share forecast

What is BGNE's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
-$8.20
Avg 2 year Forecast
-$3.10
Avg 3 year Forecast
$4.01

BGNE revenue forecast

What is BGNE's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$3.2B+14.49%
Avg 2 year Forecast
$4.1B+47.02%
Avg 3 year Forecast
$5.3B+90.52%
BGNE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BGNE revenue growth forecast

How is BGNE forecast to perform vs Biotechnology companies and vs the US market?
Company
23.57%
Industry
35.7%
Market
9.86%
BGNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BGNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BGNE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BGNE$156.11$236.50+51.50%Strong Buy
RPRX$26.91$39.50+46.79%Strong Buy
BMRN$83.78$98.90+18.05%Buy
GMAB$26.03$45.75+75.76%Buy
SRPT$160.72$181.94+13.20%Strong Buy

Beigene Stock Forecast FAQ

Is Beigene Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: BGNE) stock is to Strong Buy BGNE stock.

Out of 4 analysts, 3 (75%) are recommending BGNE as a Strong Buy, 0 (0%) are recommending BGNE as a Buy, 1 (25%) are recommending BGNE as a Hold, 0 (0%) are recommending BGNE as a Sell, and 0 (0%) are recommending BGNE as a Strong Sell.

If you're new to stock investing, here's how to buy Beigene stock.

What is BGNE's earnings growth forecast for 2024-2026?

(NASDAQ: BGNE) Beigene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.95%.

Beigene's earnings in 2024 is -$784,427,000.On average, 6 Wall Street analysts forecast BGNE's earnings for 2024 to be -$11,143,613,395, with the lowest BGNE earnings forecast at -$13,228,172,110, and the highest BGNE earnings forecast at -$5,098,216,384. On average, 6 Wall Street analysts forecast BGNE's earnings for 2025 to be -$4,212,214,352, with the lowest BGNE earnings forecast at -$11,909,433,472, and the highest BGNE earnings forecast at $2,039,286,554.

In 2026, BGNE is forecast to generate $5,451,692,720 in earnings, with the lowest earnings forecast at -$2,474,334,352 and the highest earnings forecast at $14,710,053,673.

What is BGNE's revenue growth forecast for 2024-2026?

(NASDAQ: BGNE) Beigene's forecast annual revenue growth rate of 23.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.7%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.86%.

Beigene's revenue in 2024 is $2,762,630,000.On average, 4 Wall Street analysts forecast BGNE's revenue for 2024 to be $4,299,930,864,761, with the lowest BGNE revenue forecast at $4,128,508,437,073, and the highest BGNE revenue forecast at $4,500,773,399,793. On average, 4 Wall Street analysts forecast BGNE's revenue for 2025 to be $5,521,687,831,828, with the lowest BGNE revenue forecast at $5,245,860,730,223, and the highest BGNE revenue forecast at $5,786,176,500,195.

In 2026, BGNE is forecast to generate $7,155,505,758,944 in revenue, with the lowest revenue forecast at $6,641,888,328,531 and the highest revenue forecast at $8,256,146,778,551.

What is BGNE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BGNE) forecast ROA is 191.3%, which is higher than the forecast US Biotechnology industry average of 31.22%.

What is BGNE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year BGNE price target, the average BGNE price target is $236.50, with the highest BGNE stock price forecast at $345.00 and the lowest BGNE stock price forecast at $161.00.

On average, Wall Street analysts predict that Beigene's share price could reach $236.50 by May 9, 2025. The average Beigene stock price prediction forecasts a potential upside of 51.5% from the current BGNE share price of $156.11.

What is BGNE's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: BGNE) Beigene's current Earnings Per Share (EPS) is -$0.58. On average, analysts forecast that BGNE's EPS will be -$8.20 for 2024, with the lowest EPS forecast at -$9.73, and the highest EPS forecast at -$3.75. On average, analysts forecast that BGNE's EPS will be -$3.10 for 2025, with the lowest EPS forecast at -$8.76, and the highest EPS forecast at $1.50. In 2026, BGNE's EPS is forecast to hit $4.01 (min: -$1.82, max: $10.82).

What is BGNE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BGNE) forecast ROE is 322.65%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.